CRISPR-based ex vivo gene editing of donor organs
Source abstract
Abstract
Donor organs are frequently discarded because of concerns about quality or pathogen risk, challenges that could be mitigated through ex vivo gene editing or silencing during machine perfusion. Here, we discuss the development of CRISPR-based approaches for ex vivo gene silencing in human donor organs, from proof of concept in kidney biopsies to the challenges of organ-scale translation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: CRISPR and Genetic Engineering · Organ Donation and Transplantation · RNA regulation and disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (10)
Show source-provided references
1. Li, X., Ding, R. & Cai, J. Organ transplantation: current status, challenges, and future prospects. MedComm 7, e70567 (2026).10.1002/mco2.70567 ↗
2. Mohan, S. et al. Factors leading to the discard of deceased donor kidneys in the United States. Kidney Int. 94, 187–198 (2018).10.1016/j.kint.2018.02.016 ↗
3. Nasralla, D. et al. A randomized trial of normothermic preservation in liver transplantation. Nature 557, 50–56 (2018).10.1038/s41586-018-0047-9 ↗
4. Moers, C. et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N. Engl. J. Med. 360, 7–19 (2009).10.1056/NEJMoa0802289 ↗
5. Tingle, S. J. et al. Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantation. Cochrane Database Syst. Rev. 7, CD011671 (2024).
6. Andrijevic, D. et al. Mechanisms and strategies for organ recovery. Nat. Rev. Bioeng. 3, 596–611 (2025).10.1038/s44222-025-00293-7 ↗
7. Orosco, C. et al. DNA-guided CRISPR–Cas12 for cellular RNA targeting. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03129-w (2026).10.1038/s41587-026-03129-w ↗
8. Mendiola Pla, M. & Bowles, D. E. Ex vivo gene therapy in organ transplantation: considerations and clinical translation. Hum. Gene Ther. 35, 284–297 (2024).10.1089/hum.2023.193 ↗
9. Rabelink, T. J. et al. Opportunities and challenges with the implementation of normothermic machine perfusion in kidney transplantation. Nat. Commun. 16, 6883 (2025).10.1038/s41467-025-60410-3 ↗
10. Molitoris, B. A. et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J. Am. Soc. Nephrol. 20, 1754–1764 (2009).10.1681/ASN.2008111204 ↗